| Symbol | SPRB |
|---|---|
| Name | SPRUCE BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | - |
| Address | 94080 United States CA 611 Gateway Boulevard Suite 740 |
| Telephone | (415) 655-4168 |
| Fax | — |
| — | |
| Website | http://www.sprucebio.com/ |
| Incorporation | US |
| Incorporated On | 2016 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | BDO USA, LLP; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001683553 |
| Description | Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. The company has a diverse portfolio of product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. Additional info from NASDAQ: Additional info from OTC: |
New Form SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000947871-26-000803 <b>Size:</b> 16 KB
Read moreNew Form SCHEDULE 13G/A - SPRUCE BIOSCIENCES, INC. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097316 <b>Size:</b> 11 KB
Read moreNew Form SCHEDULE 13G/A - SPRUCE BIOSCIENCES, INC. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097149 <b>Size:</b> 18 KB
Read moreNew Form SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001535264-26-000044 <b>Size:</b> 8 KB
Read more(30% Negative) SPRUCE BIOSCIENCES, INC. (SPRB) Reports Q3 2026 Financial Results
Read moreSpruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Read moreCure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
Read moreSpruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
Read moreQuartel Adrian W 🟢 acquired 13.0K shares (1 derivative) of SPRUCE BIOSCIENCES, INC. (SPRB) Transaction Date: Jul 27, 2026 | Filing ID: 000007
Read moreNew Form 3 - SPRUCE BIOSCIENCES, INC. <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0001910132-26-000006 <b>Size:</b> 10 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07733856 | Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type II… | — | Mucopolysaccharidosis Type IIIB | Available | — | — | ClinicalTrials.gov |
| NCT07579910 | Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfi… | Phase3 | MPS IIIB | Not_Yet_Recruiting | 2026-12-01 | 2033-08-01 | ClinicalTrials.gov |
| NCT05370521 | A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary… | Phase2 | Polycystic Ovary Syndrome | Terminated | 2022-05-15 | 2023-08-31 | ClinicalTrials.gov |
| NCT05128942 | A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Chil… | Phase2 | Congenital Adrenal Hyperplasia | Terminated | 2021-12-10 | 2025-01-31 | ClinicalTrials.gov |
| NCT04544410 | A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Dose… | Phase2 | Congenital Adrenal Hyperplasia | Terminated | 2021-02-22 | 2025-01-31 | ClinicalTrials.gov |
| NCT04457336 | A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH | Phase2 | Congenital Adrenal Hyperplasia | Terminated | 2020-08-26 | 2024-05-23 | ClinicalTrials.gov |
| NCT03687242 | Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Co… | Phase2 | Congenital Adrenal Hyperplasia | Completed | 2018-09-06 | 2019-08-09 | ClinicalTrials.gov |
| NCT03257462 | Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia | Phase2 | Congenital Adrenal Hyperplasia | Completed | 2017-07-12 | 2019-03-29 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Tralesinidase alfa (TA) | Other | Phase PHASE3 | MPS IIIB | NOT_YET_RECRUITING | NCT07579910 |
| Tralesinidase alfa (TA) | Other | Preclinical | Mucopolysaccharidosis Type IIIB | AVAILABLE | NCT07733856 |
| Tralesinidase alfa (TA) | Other | Phase PHASE3 | MPS IIIB | NOT_YET_RECRUITING | NCT07579910 |
| Tralesinidase alfa (TA) | Other | Phase PHASE3 | MPS IIIB | NOT_YET_RECRUITING | NCT07579910 |
| Tralesinidase alfa (TA) | Other | Phase PHASE3 | MPS IIIB | NOT_YET_RECRUITING | NCT07579910 |
| Tralesinidase alfa (TA) | Other | Phase PHASE3 | MPS IIIB | NOT_YET_RECRUITING | NCT07579910 |
| Tralesinidase alfa (TA) | Other | Phase PHASE3 | MPS IIIB | NOT_YET_RECRUITING | NCT07579910 |
| Tralesinidase alfa (TA) | Other | Phase PHASE3 | MPS IIIB | NOT_YET_RECRUITING | NCT07579910 |
| SPR001 | Other | Phase PHASE2 | Congenital Adrenal Hyperplasia | COMPLETED | NCT03687242 |
| Tildacerfont/Placebo | Other | Phase PHASE2 | Congenital Adrenal Hyperplasia | TERMINATED | NCT04457336 |
| Tildacerfont/Placebo | Other | Phase PHASE2 | Congenital Adrenal Hyperplasia | TERMINATED | NCT04544410 |
| Placebo | Other | Phase PHASE2 | Polycystic Ovary Syndrome | TERMINATED | NCT05370521 |
| Tildacerfont | Other | Phase PHASE2 | Polycystic Ovary Syndrome | TERMINATED | NCT05370521 |
| SPR001 | Other | Phase PHASE2 | Congenital Adrenal Hyperplasia | COMPLETED | NCT03257462 |
| Tildacerfont | Other | Phase PHASE2 | Congenital Adrenal Hyperplasia | TERMINATED | NCT05128942 |